Abstract
COVID-19 is associated with an increased risk for thrombotic complications. The trials investigating the optimal thromboprophylactic dose are performed in challenging times and seemingly produce conflicting evidence. The burdensome circumstances, divergent endpoints, and different analytical approaches hamper comparison and extrapolation of available evidence. Most importantly, clinicians should provide thromboprophylaxis in hospitalized COVID-19 patients while (re)assessing bleeding and thrombotic risk frequently. The COVID-19 Thromboprophylaxis Working Group of the BSTH updated its guidance document. It aims to summarize the available evidence critically and to guide clinicians in providing the best possible thromboprophylaxis.
| Original language | English |
|---|---|
| Pages (from-to) | 497-508 |
| Number of pages | 12 |
| Journal | Acta Clinica Belgica |
| Volume | 78 |
| Issue number | 6 |
| Early online date | 7 Aug 2023 |
| DOIs | |
| Publication status | Published - Dec 2023 |
Bibliographical note
Publisher Copyright:© Belgian Society of Internal Medicine and Royal Belgian Society of Laboratory Medicine (2023).
Keywords
- COVID-19
- Practice guideline
- Anticoagulants
- thrombosis
Fingerprint
Dive into the research topics of 'The 2023 Belgian clinical guidance on anticoagulation management in hospitalized and ambulatory COVID-19 patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver